Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia

Leukemia Research

Volumn 30, Issue 2, 2006, Pages 204-210

  Lee, Je Hwan ^a   Choi, Seong Jun ^a   Lee, Jung Hee ^a   Lee, Young Shin ^a   Seol, Miee ^a   Ryu, Seong Gil ^a   Jang, Seongsoo ^a   Park, Chan Jeoung ^a   Chi, Hyun Sook ^a   Lee, Jung Shin ^a   Kim, Woo Kun ^a   Lee, Kyoo Hyung ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Acute myelogenous leukemia; Continuous infusion; Early relapse; Intermediate dose cytarabine; Refractory

Indexed keywords

ANTILEUKEMIC AGENT; CYTARABINE; ETOPOSIDE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; INFECTION COMPLICATION; LEUKEMIA REMISSION; LIVER TOXICITY; MALE; METABOLIC DISORDER; NEPHROTOXICITY; NEUROTOXICITY; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY DISTRESS; SALVAGE THERAPY; SEIZURE; SKIN TOXICITY; SURVIVAL TIME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; ETOPOSIDE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MITOXANTRONE; PROGNOSIS; PROSPECTIVE STUDIES; SALVAGE THERAPY;

EID: 28844432105     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2005.06.013     Document Type: Article

References (45)

1. B. Lowenberg, J.R. Downing, and A. Burnett Acute myeloid leukemia N Engl J Med 341 1999 1051 1062
2. J.M. Rowe What is the best induction regimen for acute myelogenous leukemia? Leukemia 12 Suppl 1 1998 S16 S19
3. T. Robak, and A. Wrzesien-Kus The search for optimal treatment in relapsed and refractory acute myeloid leukemia Leuk Lymphoma 43 2002 281 291
4. L.H. Leopold, and R. Willemze The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature Leuk Lymphoma 43 2002 1715 1727
5. F. Ferrara, S. Palmieri, and G. Mele Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia Haematologica 89 2004 998 1008
6. E.H. Estey Treatment of relapsed and refractory acute myelogenous leukemia Leukemia 14 2000 476 479
7. S. Stanisic, and M. Kalaycio Treatment of refractory and relapsed acute myelogenous leukemia Expert Rev Anticancer Ther 2 2002 287 295
8. M. Vignetti, E. Orsini, M.C. Petti, M.L. Moleti, C. Andrizzi, and R.M. Pinto Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: a single-centre experience Ann Oncol 7 1996 933 938
9. M. Michieli, D. Damiani, A. Ermacora, P. Masolini, D. Raspadori, and G. Visani P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications Br J Haematol 104 1999 328 335
10. P.A. te Boekhorst, B. Lowenberg, J. van Kapel, K. Nooter, and P. Sonneveld Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia Leukemia 9 1995 1025 1031
11. E. Cros, L. Jordheim, C. Dumontet, and C.M. Galmarini Problems related to resistance to cytarabine in acute myeloid leukemia Leuk Lymphoma 45 2004 1123 1132
12. R.L. Capizzi, J.C. White, B.L. Powell, and F. Perrino Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine Semin Hematol 28 1991 54 69
13. A. Hamada, T. Kawaguchi, and M. Nakano Clinical pharmacokinetics of cytarabine formulations Clin Pharmacokinet 41 2002 705 718
14. W. Plunkett, J.O. Liliemark, E. Estey, and M.J. Keating Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C Semin Oncol 14 1987 159 166
15. J. De La Serna, J. Francisco Tomas, C. Solano, M.L. Garcia de Paredes, J. Campbell, and C. Grande Idarubicin and intermediate dose ARA-C followed by consolidation chemotherapy or bone marrow transplantation in relapsed or refractory acute myeloid leukemia Leuk Lymphoma 25 1997 365 372
16. T. De Witte, S. Suciu, D. Selleslag, B. Labar, K. Roozendaal, and R. Zittoun Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phase-II study (no. 06901) of the EORTC Leukemia Cooperative Group Ann Hematol 72 1996 119 124
17. A. Spadea, M.C. Petti, P. Fazi, M.L. Vegna, W. Arcese, and G. Avvisati Mitoxantrone, etoposide and intermediate-dose Ara-C (MEC): an effective regimen for poor risk acute myeloid leukemia Leukemia 7 1993 549 552
18. S. Amadori, W. Arcese, G. Isacchi, G. Meloni, M.C. Petti, and B. Monarca Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia J Clin Oncol 9 1991 1210 1214
19. R.S. Walters, H.M. Kantarjian, M.J. Keating, W.K. Plunkett, E.H. Estey, and B. Andersson Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia Cancer 62 1988 677 682
20. W. Hiddemann, H. Kreutzmann, R. Donhuijsen-Ant, M. Planker, F.C. Wendt, and T. Buchner High-dose cytosine arabinoside and mitoxantrone (HAM) for the treatment of refractory acute lymphoblastic leukemia Onkologie 10 1987 11 12
21. R.H. Herzig, S.N. Wolff, H.M. Lazarus, G.L. Phillips, C. Karanes, and G.P. Herzig High-dose cytosine arabinoside therapy for refractory leukemia Blood 62 1983 361 369
22. A. Leahey, K. Kelly, L.B. Rorke, and B. Lange A phase I/II study of idarubicin (Ida) with continuous infusion fludarabine (F-ara-A) and cytarabine (ara-C) for refractory or recurrent pediatric acute myeloid leukemia (AML) J Pediatr Hematol Oncol 19 1997 304 308
23. P.A. Dinndorf, V.I. Avramis, S. Wiersma, M.D. Krailo, W. Liu-Mares, and N.L. Seibel Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group J Clin Oncol 15 1997 2780 2785
24. The Children's Cancer Group V.I. Avramis, S. Wiersma, M.D. Krailo, L.V. Ramilo-Torno, A. Sharpe, and W. Liu-Mares Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias Clin Cancer Res 4 1998 45 52
25. K.R. Crews, V. Gandhi, D.K. Srivastava, B.I. Razzouk, X. Tong, and F.G. Behm Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia J Clin Oncol 20 2002 4217 4224
26. H. Bahng, J.H. Lee, J.H. Ahn, J.S. Lee, S.H. Kim, and W.K. Kim Combination chemotherapy utilizing continuous infusion of intermediate-dose cytarabine for refractory or recurrent acute myeloid leukemia Leuk Res 25 2001 213 216
27. B.D. Cheson, J.M. Bennett, K.J. Kopecky, T. Buchner, C.L. Willman, E.H. Estey Revised recommendations of the International Working Group for Diagnosis Standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia J Clin Oncol 21 2003 4642 4649
28. M.L. Slovak, K.J. Kopecky, P.A. Cassileth, D.H. Harrington, K.S. Theil, and A. Mohamed Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study Blood 96 2000 4075 4083
29. A. Tafuri, C. Gregorj, M.T. Petrucci, M.R. Ricciardi, M. Mancini, and G. Cimino MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia Blood 100 2002 974 981
30. E. Estey, P. Thall, M. Andreeff, M. Beran, H. Kantarjian, and S. O'Brien Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor J Clin Oncol 12 1994 671 678
31. G. Jackson, P. Taylor, G.M. Smith, R. Marcus, A. Smith, and P. Chu A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation Br J Haematol 112 2001 127 137
32. D. Pastore, G. Specchia, P. Carluccio, A. Liso, A. Mestice, and R. Rizzi FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience Ann Hematol 82 2003 231 235
33. M. Hanel, K. Friedrichsen, A. Hanel, R. Herbst, A. Morgner, and S. Neser Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia Onkologie 24 2001 356 360
34. X. Thomas, P. Fenaux, H. Dombret, S. Delair, F. Dreyfus, and H. Tilly Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial) Leukemia 13 1999 1214 1220
35. E. Archimbaud, X. Thomas, V. Leblond, M. Michallet, P. Fenaux, and C. Cordonnier Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial J Clin Oncol 13 1995 11 18
36. R.C. Donehower, J.E. Karp, and P.J. Burke Pharmacology and toxicity of high-dose cytarabine by 72 h continuous infusion Cancer Treat Rep 70 1986 1059 1065
37. J.F. Seymour, P. Huang, W. Plunkett, and V. Gandhi Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule Clin Cancer Res 2 1996 653 658
38. C.P. Leith, K.J. Kopecky, I.M. Chen, L. Eijdems, M.L. Slovak, and T.S. McConnell Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study Blood 94 1999 1086 1099
39. K. Mrozek, K. Heinonen, A. de la Chapelle, and C.D. Bloomfield Clinical significance of cytogenetics in acute myeloid leukemia Semin Oncol 24 1997 17 31
40. W. Kern, T. Haferlach, S. Schnittger, W.D. Ludwig, W. Hiddemann, and C. Schoch Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy Leukemia 16 2002 2084 2091
41. F. Lo-Coco, G. Cimino, M. Breccia, N.I. Noguera, D. Diverio, and E. Finolezzi Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia Blood 104 2004 1995 1999
42. D. Grimwade, and F. Lo Coco Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia Leukemia 16 2002 1959 1973
43. J. Krauter, K. Gorlich, O. Ottmann, M. Lubbert, H. Dohner, and W. Heit Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias J Clin Oncol 21 2003 4413 4422
44. S. Schnittger, M. Weisser, C. Schoch, W. Hiddemann, T. Haferlach, and W. Kern New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts Blood 102 2003 2746 2755
45. J.F. San Miguel, A. Martinez, A. Macedo, M.B. Vidriales, C. Lopez-Berges, and M. Gonzalez Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients Blood 90 1997 2465 2470